UCB.BR : Summary for UCB - Yahoo Finance

U.S. Markets closed

UCB S.A. (UCB.BR)


Brussels - Brussels Delayed Price. Currency in EUR
Add to watchlist
70.80+0.04 (+0.06%)
At close: 5:35PM CET
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close70.76
Open70.87
Bid64.00 x 203800
Ask66.00 x 10000
Day's Range70.50 - 71.19
52 Week Range54.84 - 74.72
Volume278,714
Avg. Volume308,812
Market Cap13.33B
BetaN/A
PE Ratio (TTM)20.52
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire2 days ago

    UCB: CONVENING NOTICE TO ATTEND THE GENERAL MEETING OF SHAREHOLDERS

    *** Unofficial English translation - For convenience purposes only *** UCB SA/NV - Public Limited Liability Company Allée de la Recherche 60, 1070 Brussels Enterprise nr. 0403.053.608 (RLE Brussels) (" ...

  • PR Newswire10 days ago

    UCB Launches Wellness 4U, an Innovative and Comprehensive Health and Wellness Program for Patients with Immunologic Diseases

    ATLANTA, March 15, 2017 /PRNewswire/ -- UCB, a global biopharmaceutical company focusing on immunology, neurology and bone treatments and research, has launched Wellness 4U™, an insights-driven health and wellness program that is dedicated to promoting healthier lifestyles. Wellness 4U is a multi-channel health and wellness program that utilizes several initiatives aimed to elevate patient outcomes beyond therapeutic support for people living with immunologic disorders and their healthcare professionals. Key Wellness 4U programs include a Wellness 4U Activity Tracker, a health outcomes research collaboration with the IBD Support Foundation, a national wellness education panel speaker event series addressing the entire care team and a nurse practitioner/physician's assistant educational initiative.

  • PR Newswire20 days ago

    First CIMZIA® (certolizumab pegol) Study of Its Kind Showed Minimal to No Transfer of Drug from Mother's Plasma to Breast Milk

    BRUSSELS, March 6, 2017 /PRNewswire/ -- Today UCB announced results from the CRADLE study, the first lactation study designed to evaluate CIMZIA® (certolizumab pegol) concentrations in human mature breast milk and to estimate the average daily infant dose of the drug in maternal breast milk, in accordance with guidance from the US Food & Drug Administration. The study used a bioanalytical assay specifically designed for CIMZIA, offering significantly improved sensitivity and specificity over previously used plasma assays. The reported results indicate minimal to no transfer of CIMZIA into breast milk, a minimal average daily infant dose, and a relative infant dose, considered to be in the acceptable range for breastfeeding.